Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapy-Results From the SEARCH Database

Charles D. Scales, Joseph C. Presti, Christopher J. Kane, Martha K. Terris, William J. Aronson, Christopher L. Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: For men with low risk prostate cancer it was recently proposed that ablative treatment to the affected side may decrease morbidity, while maintaining good oncological outcomes. However, few studies have assessed the correlation between biopsy parameters and pathological outcome (unilateral vs bilateral disease). Materials and Methods: Using the Shared Equal Access Regional Cancer Hospital Database of men treated with radical prostatectomy at multiple equal access medical centers we retrospectively examined the records of 261 men with clinical stage T1c or T2a prostate cancer, prostate specific antigen less than 10 ng/ml, Gleason sum 6 or less and only 1 or 2 ipsilateral positive cores on at least sextant biopsy. We compared clinical characteristics between men with pathologically unilateral disease or less (pT2b or less) and men with pathologically bilateral disease or extraprostatic extension (pT2c or greater). To determine the significant predictors of pT2c or greater disease we used a multivariate logistic regression model. Results: Of the cohort of 261 men with low risk prostate cancer only 93 (35.1%) had unilateral or no evidence of disease following examination of radical prostatectomy specimens. Men with pathologically unilateral or less disease did not differ from those with bilateral or more advanced disease by age, prostate specific antigen, clinical stage, body mass index or number of positive biopsy cores (1 vs 2). On multivariate analysis no clinical feature was significantly related to pathologically unilateral or less vs bilateral or greater disease. Conclusions: The majority of men with low risk prostate cancer and 1 or 2 ipsilateral positive biopsy cores have pathologically bilateral disease. Therefore, strategies for unilateral treatment of prostate cancer are unlikely to be curative for these men.

Original languageEnglish (US)
Pages (from-to)1249-1252
Number of pages4
JournalJournal of Urology
Volume178
Issue number4
DOIs
StatePublished - Oct 1 2007

Fingerprint

Prostatic Neoplasms
Databases
Biopsy
Therapeutics
Prostate-Specific Antigen
Prostatectomy
Logistic Models
Cancer Care Facilities
Body Mass Index
Multivariate Analysis
Morbidity

Keywords

  • biopsy
  • prostate
  • prostatectomy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Predicting Unilateral Prostate Cancer Based on Biopsy Features : Implications for Focal Ablative Therapy-Results From the SEARCH Database. / Scales, Charles D.; Presti, Joseph C.; Kane, Christopher J.; Terris, Martha K.; Aronson, William J.; Amling, Christopher L.; Freedland, Stephen J.

In: Journal of Urology, Vol. 178, No. 4, 01.10.2007, p. 1249-1252.

Research output: Contribution to journalArticle

Scales, Charles D. ; Presti, Joseph C. ; Kane, Christopher J. ; Terris, Martha K. ; Aronson, William J. ; Amling, Christopher L. ; Freedland, Stephen J. / Predicting Unilateral Prostate Cancer Based on Biopsy Features : Implications for Focal Ablative Therapy-Results From the SEARCH Database. In: Journal of Urology. 2007 ; Vol. 178, No. 4. pp. 1249-1252.
@article{fad542509b534c038884bda0fc9bf713,
title = "Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapy-Results From the SEARCH Database",
abstract = "Purpose: For men with low risk prostate cancer it was recently proposed that ablative treatment to the affected side may decrease morbidity, while maintaining good oncological outcomes. However, few studies have assessed the correlation between biopsy parameters and pathological outcome (unilateral vs bilateral disease). Materials and Methods: Using the Shared Equal Access Regional Cancer Hospital Database of men treated with radical prostatectomy at multiple equal access medical centers we retrospectively examined the records of 261 men with clinical stage T1c or T2a prostate cancer, prostate specific antigen less than 10 ng/ml, Gleason sum 6 or less and only 1 or 2 ipsilateral positive cores on at least sextant biopsy. We compared clinical characteristics between men with pathologically unilateral disease or less (pT2b or less) and men with pathologically bilateral disease or extraprostatic extension (pT2c or greater). To determine the significant predictors of pT2c or greater disease we used a multivariate logistic regression model. Results: Of the cohort of 261 men with low risk prostate cancer only 93 (35.1{\%}) had unilateral or no evidence of disease following examination of radical prostatectomy specimens. Men with pathologically unilateral or less disease did not differ from those with bilateral or more advanced disease by age, prostate specific antigen, clinical stage, body mass index or number of positive biopsy cores (1 vs 2). On multivariate analysis no clinical feature was significantly related to pathologically unilateral or less vs bilateral or greater disease. Conclusions: The majority of men with low risk prostate cancer and 1 or 2 ipsilateral positive biopsy cores have pathologically bilateral disease. Therefore, strategies for unilateral treatment of prostate cancer are unlikely to be curative for these men.",
keywords = "biopsy, prostate, prostatectomy, prostatic neoplasms",
author = "Scales, {Charles D.} and Presti, {Joseph C.} and Kane, {Christopher J.} and Terris, {Martha K.} and Aronson, {William J.} and Amling, {Christopher L.} and Freedland, {Stephen J.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.juro.2007.05.151",
language = "English (US)",
volume = "178",
pages = "1249--1252",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Predicting Unilateral Prostate Cancer Based on Biopsy Features

T2 - Implications for Focal Ablative Therapy-Results From the SEARCH Database

AU - Scales, Charles D.

AU - Presti, Joseph C.

AU - Kane, Christopher J.

AU - Terris, Martha K.

AU - Aronson, William J.

AU - Amling, Christopher L.

AU - Freedland, Stephen J.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: For men with low risk prostate cancer it was recently proposed that ablative treatment to the affected side may decrease morbidity, while maintaining good oncological outcomes. However, few studies have assessed the correlation between biopsy parameters and pathological outcome (unilateral vs bilateral disease). Materials and Methods: Using the Shared Equal Access Regional Cancer Hospital Database of men treated with radical prostatectomy at multiple equal access medical centers we retrospectively examined the records of 261 men with clinical stage T1c or T2a prostate cancer, prostate specific antigen less than 10 ng/ml, Gleason sum 6 or less and only 1 or 2 ipsilateral positive cores on at least sextant biopsy. We compared clinical characteristics between men with pathologically unilateral disease or less (pT2b or less) and men with pathologically bilateral disease or extraprostatic extension (pT2c or greater). To determine the significant predictors of pT2c or greater disease we used a multivariate logistic regression model. Results: Of the cohort of 261 men with low risk prostate cancer only 93 (35.1%) had unilateral or no evidence of disease following examination of radical prostatectomy specimens. Men with pathologically unilateral or less disease did not differ from those with bilateral or more advanced disease by age, prostate specific antigen, clinical stage, body mass index or number of positive biopsy cores (1 vs 2). On multivariate analysis no clinical feature was significantly related to pathologically unilateral or less vs bilateral or greater disease. Conclusions: The majority of men with low risk prostate cancer and 1 or 2 ipsilateral positive biopsy cores have pathologically bilateral disease. Therefore, strategies for unilateral treatment of prostate cancer are unlikely to be curative for these men.

AB - Purpose: For men with low risk prostate cancer it was recently proposed that ablative treatment to the affected side may decrease morbidity, while maintaining good oncological outcomes. However, few studies have assessed the correlation between biopsy parameters and pathological outcome (unilateral vs bilateral disease). Materials and Methods: Using the Shared Equal Access Regional Cancer Hospital Database of men treated with radical prostatectomy at multiple equal access medical centers we retrospectively examined the records of 261 men with clinical stage T1c or T2a prostate cancer, prostate specific antigen less than 10 ng/ml, Gleason sum 6 or less and only 1 or 2 ipsilateral positive cores on at least sextant biopsy. We compared clinical characteristics between men with pathologically unilateral disease or less (pT2b or less) and men with pathologically bilateral disease or extraprostatic extension (pT2c or greater). To determine the significant predictors of pT2c or greater disease we used a multivariate logistic regression model. Results: Of the cohort of 261 men with low risk prostate cancer only 93 (35.1%) had unilateral or no evidence of disease following examination of radical prostatectomy specimens. Men with pathologically unilateral or less disease did not differ from those with bilateral or more advanced disease by age, prostate specific antigen, clinical stage, body mass index or number of positive biopsy cores (1 vs 2). On multivariate analysis no clinical feature was significantly related to pathologically unilateral or less vs bilateral or greater disease. Conclusions: The majority of men with low risk prostate cancer and 1 or 2 ipsilateral positive biopsy cores have pathologically bilateral disease. Therefore, strategies for unilateral treatment of prostate cancer are unlikely to be curative for these men.

KW - biopsy

KW - prostate

KW - prostatectomy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=34548504821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548504821&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.05.151

DO - 10.1016/j.juro.2007.05.151

M3 - Article

C2 - 17698131

AN - SCOPUS:34548504821

VL - 178

SP - 1249

EP - 1252

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -